Sorrento Therapeutics, Inc.
Case Number:
4:23-bk-90085
Court:
Nature of Suit:
Firms
- Martin P. Eramo APC
- Gray Reed
- Christian Levine Law Group
- Finch Thornton
- Coats Rose
- Chapman & Cutler
- Bressler Amery
- WilmerHale
- Warshaw Burstein
- Rusty Hardin & Associates
- ASK LLP
- Harvest LLP
- Glenn Agre
- Pillsbury Winthrop
- Law Office of Liz Freeman
- Pashman Stein
- Maynard Nexsen
- Sidley Austin
- Gibbs Giden
- Sheppard Mullin
- Reed Smith
- Miller Nash LLP
- Ferguson Braswell
- Katten Muchin
- Tran Singh
- Duane Morris
- Greenberg Traurig
- Franklin Soto Leeds
- Probus Law Firm
- McGuireWoods
- Cowles & Thompson
- Doyle Restrepo
- Quinn Emanuel
- Porter Hedges
- Davis Graham
- Andrews Myers
- Troutman
- Haynes Boone
- Tucker Arensberg
- Ohashi & Horn
- Husch Blackwell
- DLA Piper
- Buchalter APC
- K&L Gates
- Baker Botts
- Kane Russell
- Ross Smith & Binford
- Munsch Hardt
- Thompson Coburn
- Jones Walker
- Clark Hill
- Shook Hardy
- Norton Rose
- Paul Hastings
- Jackson Walker LLP
- Latham & Watkins
- Milbank LLP
Companies
- The Scripps Research Institute
- Cetera Financial Institutions
- LPL Financial
- Phillip Capital Inc.
- Pershing Group LLC
- HSBC Holdings PLC
- Fortis Advisors LLC
- PCI Pharma Services
- The Charles Schwab Corp.
- Sorrento Therapeutics Inc.
- Interactive Brokers Group Inc.
- BMO Harris Bank NA
- New England Biolabs Inc.
- BNY Mellon Investment Management
- Wedbush Securities Inc.
- FMR LLC
- Mayo Foundation for Medical Education and Research
- Edward D. Jones & Co. LP
- Protiviti Inc.
- Raymond James Financial Inc.
- American Express Co.
- Charles River Laboratories International Inc.
- Bank of America Corp.
- TR Capital Management LLC
- Precision for Medicine Holdings Inc.
- FTI Consulting Inc.
- JPMorgan Chase & Co.
- Barclays PLC
- Apex Clearing Corporation
- Stretto Inc.
- The Goldman Sachs Group Inc.
- BMO Capital Markets Corp.
- Robert Half Inc.
- NantWorks LLC
- Oracle Corp.
- ABN AMRO Bank NV
- Emas Pharma Ltd.
- LPL Financial Holdings Inc.
- Kilroy Realty Corporation
- Prospect Medical Holdings Inc.
- Moelis & Co.
- The Bank of New York Mellon Corp.
- Morgan Stanley
- UBS Group AG
Sectors & Industries:
-
April 04, 2025
Under The Radar: Bankruptcy News You May Have Missed
A bankruptcy judge approved the retention of a repossession agent that the trustee for Chinese exile Miles Guo used to recover a small private jet from his son, a federal court stood by a ruling that refused to let Sorrento Therapeutics shareholders probe a matter related to a former judge's romantic relationship, and shoe designer Zigi USA filed its Chapter 11 plan. These are some of the bankruptcy stories you may have missed in the last week.
-
August 12, 2024
Sorrento Shareholders' Fee Objection Too Late, Judge Says
A Texas bankruptcy judge on Monday found a group of Sorrento Therapeutics shareholders objected too late to proposed fee payments to Jackson Walker LLP for its work on Sorrento's Chapter 11 case, denying them the opportunity to present evidence at a fee hearing next month.
-
July 11, 2024
Sorrento Investors Rip Atty Fee Requests Over 'Scant' Results
A group of Sorrento Therapeutics Inc. shareholders has asked a Texas bankruptcy judge to reject $50 million in fee applications by lawyers for the drug developer, charging that the Chapter 11 case has been a "disaster for all stakeholders other than for professionals."
-
May 23, 2024
Ex-Judge Pushed False Narrative On Atty Romance, Firm Says
U.S. Bankruptcy Judge David R. Jones of Texas, who resigned last year after his secret relationship with a Jackson Walker LLP partner was revealed, attempted to head off rumors about the relationship by asking the firm to file a false, partial disclosure in 2022, the firm alleged.
-
March 26, 2024
Sorrento Gets Green Light To Delay $21M Ch. 11 Sale
Drug developer Sorrento Therapeutics can push the close of its $20.9 million asset sale from Thursday to April 1, a Texas bankruptcy judge ruled Tuesday, after attorneys for the debtor said they reached new terms for the deal that will help fund the company as it winds down under its Chapter 11 plan.
-
March 12, 2024
Sorrento Ch. 11 Will Stay In Texas
A Texas bankruptcy judge Tuesday denied requests to transfer the Chapter 11 case of drug developer Sorrento Therapeutics Inc. out of the Lone Star State for having insufficient ties to the venue.
-
March 08, 2024
Sorrento Gets OK For $2M Ch. 11 Funding Infusion, Asset Sale
A Texas bankruptcy judge on Friday approved drug developer Sorrento Therapeutics Inc.'s bid for an asset sale and $2 million in funds to fuel its Chapter 11 case, saying they represented the only option outside of a transition to Chapter 7.
-
March 04, 2024
Sorrento Creditors Fight To Keep Ch. 11 In Texas
Creditors for drug developer Sorrento Therapeutics Inc. have asked a Texas bankruptcy judge to keep the company's Chapter 11 case in the Lone Star State, saying the U.S. trustee's bid to move it comes too late and wouldn't help those hoping for recoveries.
-
February 27, 2024
Latham, Jackson Walker Avoid Sanctions Over Sorrento Venue
A Texas bankruptcy judge declined to level sanctions against Latham & Watkins LLP and Jackson Walker LLP for trying to establish Texas jurisdiction for California-based Sorrento Therapeutics Inc. in its Chapter 11 bankruptcy, finding that their conduct did not amount to bankruptcy fraud.
-
February 22, 2024
Sorrento Says US Trustee's Protest Of Texas Venue Off Base
Sorrento Therapeutics Inc. told a Texas bankruptcy court the company's choice to bring a Chapter 11 in the Lone Star State was sound, so the court should ignore a call from the U.S. Trustee's Office to trash or relocate the case.